Elite in Breast Cancer

Dr. Paul K. Marcom

Hematology Oncology
4101 N Roxboro St, 
Durham, NC 
Elite in Breast Cancer
4101 N Roxboro St, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Marcom is a Hematologist Oncology provider in Durham, North Carolina. Dr. Marcom is rated as an Elite provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Breast Cancer in Men, and Angiosarcoma.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 71 articles and participated in 9 clinical trials in the study of Breast Cancer.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4101 N Roxboro St, Durham, NC 27704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Alisertib, Fulvestrant
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Veliparib, Carboplatin
Study Phase: Phase 3
A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects
A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Drug
Study Drug: GMI-1359
Study Phase: Phase 1
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Enrollment Status: Terminated
Publish Date: February 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2018
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Enrollment Status: Withdrawn
Publish Date: June 05, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

77 Total Publications

Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Journal: American journal of medicine open
Published: September 30, 2024
Similar Doctors
Distinguished in Breast Cancer
Dr. Joellen C. Speca
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Joellen C. Speca
Hematology Oncology | Hematology | Oncology

Rex Hospital Inc

4420 Lake Boone Trl, 
Raleigh, NC 
 (19.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joellen Speca is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Speca is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Smoldering Multiple Myeloma. Dr. Speca is currently accepting new patients.

Alexandra Thomas
Distinguished in Breast Cancer
Dr. Alexandra Thomas
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Alexandra Thomas
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (3.4 miles away)
919-681-6900
Experience:
31+ years
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

I am a medical oncologist, a physician providing medical treatments to cancer patients, drawn to this field by the profound relationships we foster with our patients and the dynamic scientific advancements. Building individual connections allows us to tailor care to our patients' unique needs and accompany them throughout their journey. Additionally, we contribute to pioneering new treatments, offering hope and reduced treatment-related toxicity with each passing day. Outside of work, I find joy in traveling, knitting, and cherishing moments with family. Exploring North Carolina holds a special place in my heart, as I delight in discovering more about its intricacies. Dr. Thomas is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Angiosarcoma, Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Distinguished in Breast Cancer
Dr. Lisa A. Carey
Hematology Oncology | Oncology
Distinguished in Breast Cancer
Dr. Lisa A. Carey
Hematology Oncology | Oncology

University Of North Carolina At Chapel Hill

2801 Blue Ridge Rd, 
Raleigh, NC 
 (19.2 miles away)
984-974-0500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lisa Carey is a Hematologist Oncology specialist and an Oncologist in Raleigh, North Carolina. Dr. Carey is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, and Angiosarcoma. Dr. Carey is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marcom's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile